Teva Will Stick To Hybrid Biosimilar Model, With Cash In Its Thinking
New CEO Francis Continuing To Weigh Best Use Of Capital But Pipeline A Priority
Executive Summary
Teva’s senior management spoke at length about the company’s ambitions in the biosimilar space, ahead of the planned US launch of partner Alvotech’s AVT02 proposed interchangeable high-concentration (Humira) adalimumab biosimilar on 1 July.